WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership...

We are honored to announce WuXi AppTec has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award. The award is part of the...

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series B round with investment from a consortium...

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP Manufacturing Facilities for...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities for production of TMB-355 (ibalizumab) with no...

WuXi’s Pharmaceutical Development Services Division Merges with STA

We are excited to announce that WuXi subsidiary STA Pharmaceutical Co., Ltd. (STA)  has merged with our Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as...

STA Signs Supply Agreement with TESARO

We are pleased to announce that STA Pharmaceutical Co., Ltd. (STA), a WuXi subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Capricor Therapeutics Seeking New Cell Therapy for Deadly Duchenne Disease

New breakthroughs in science, such as gene and cell therapies, give medical researchers potential new pathways to develop treatments for diseases for unmet medical...